171 related articles for article (PubMed ID: 38110304)
1. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
Yang C; Li Y
Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
[TBL] [Abstract][Full Text] [Related]
2. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
[TBL] [Abstract][Full Text] [Related]
3. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
[TBL] [Abstract][Full Text] [Related]
4. The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
Chiuzan C; Dehbi HM
Clin Trials; 2024 Jun; 21(3):350-357. PubMed ID: 38618916
[TBL] [Abstract][Full Text] [Related]
5. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
James GD; Symeonides S; Marshall J; Young J; Clack G
BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
[TBL] [Abstract][Full Text] [Related]
6. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens.
Gerard E; Zohar S; Lorenzato C; Ursino M; Riviere MK
Stat Med; 2021 Oct; 40(23):5096-5114. PubMed ID: 34259343
[TBL] [Abstract][Full Text] [Related]
7. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
Horton BJ; Wages NA; Conaway MR
Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
[TBL] [Abstract][Full Text] [Related]
8. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
Zhao D; Zhu J; Wang L
Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
[TBL] [Abstract][Full Text] [Related]
9. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
10. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
[TBL] [Abstract][Full Text] [Related]
11. Incorporating historical information to improve phase I clinical trials.
Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
[TBL] [Abstract][Full Text] [Related]
12. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
13. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
Andrillon A; Chevret S; Lee SM; Biard L
Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
[TBL] [Abstract][Full Text] [Related]
14. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs.
Zhou H; Yuan Y; Nie L
Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774
[TBL] [Abstract][Full Text] [Related]
15. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
Chen X; Zhang J; Jiang Q; Yan F
J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
Cunanan K; Koopmeiners JS
BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
[TBL] [Abstract][Full Text] [Related]
17. Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
Gerard E; Zohar S; Thai HT; Lorenzato C; Riviere MK; Ursino M
Biometrics; 2022 Mar; 78(1):300-312. PubMed ID: 33527351
[TBL] [Abstract][Full Text] [Related]
18. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
Takeda K; Taguri M; Morita S
Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
[TBL] [Abstract][Full Text] [Related]
19. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
Razaee ZS; Cook-Wiens G; Tighiouart M
Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
[TBL] [Abstract][Full Text] [Related]
20. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
O'Connell NS; Wages NA; Garrett-Mayer E
Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]